CD274 and hepatocellular carcinoma: Moreover, in 2020, the FDA approved the combination of the anti-PD-L1 antibody atezolizumab and the VEGF antagonist bevacizumab for the treatment of unresectable or metastatic HCC patients who have not received prior systemic therapy.